SCHEMBL2926317

SCHEMBL2926317

CC(C)(C)OC(=O)NC1CCN(CCCn2cc3c(-c4ccc(F)cc4)c(-c4ccncc4)c(-c4ccc(F)cc4)nc3n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 4/20 0.40
KCNA3 P22001 1/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
SSTR5 P35346 4/20 0.38
KCNH2 Q12809 2/20 0.38
CSNK1D P48730 2/20 0.37
CSNK1E P49674 2/20 0.37
PARP1 P09874 2/20 0.36
PARP2 Q9UGN5 1/20 0.36
KDM6A O15550 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926287 0.95 NPY5R (0.41) NPY5RKCNA3CKS1BSKP1SKP2
SCHEMBL1386457 0.89 SSTR5 (0.39) SSTR5KCNH2CSNK1DCSNK1EMAPK11
SCHEMBL2927353 0.86 SQOR (0.42) KCNH2CSNK1DCSNK1EMAPK11MAPK14
SCHEMBL1386935 0.85 SSTR5 (0.39) SSTR5KCNH2CSNK1DCSNK1EMAPK11
SCHEMBL1383793 0.82 MAPK14 (0.41) KCNH2CSNK1DCSNK1EMAPK11MAPK14
SCHEMBL2925845 0.82 GPR119 (0.41) KCNH2MAPK11MAPK14
SCHEMBL2927906 0.81 SQOR (0.43) KCNH2CSNK1DCSNK1EMAPK11MAPK14
SCHEMBL1385622 0.81 MAPK14 (0.39) CSNK1DCSNK1EMAPK11MAPK14
SCHEMBL1386049 0.81 MAPK14 (0.41) CSNK1DCSNK1EMAPK11MAPK14
SCHEMBL1385679 0.80 MAPK14 (0.39) KCNH2CSNK1DCSNK1EMAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 NPY5R 3119/4885KCNA3 1172/4885CKS1B 309/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 NPY5R 3346/4885KCNA3 1267/4885CKS1B 323/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 NPY5R 3346/4885KCNA3 1267/4885CKS1B 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.